Shanghai Shenqi Pharmaceutical Investment Management Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Feng Bin
Chief executive officer
CN¥480.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 13.5yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
A Look At The Fair Value Of Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:600613)
Dec 24
There May Be Reason For Hope In Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Disappointing Earnings
Nov 06Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.'s (SHSE:600613) 26% Share Price Surge Not Quite Adding Up
Oct 21Why Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Earnings Are Better Than They Seem
May 06Investor Optimism Abounds Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:600613) But Growth Is Lacking
Apr 17CEO
Feng Bin (52 yo)
13.5yrs
Tenure
CN¥480,300
Compensation
Mr. Feng Bin is a Director of Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. (formerly known as Shanghai Wingsung Investment Management Co., Ltd.) and serves as its General Manager since Jun...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 18:46 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|